InvesTrust acquired a new position in Johnson & Johnson (NYSE:JNJ – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 44,102 shares of the company’s stock, valued at approximately $6,355,000. Johnson & Johnson makes up about 1.8% of InvesTrust’s investment portfolio, making the stock its 25th biggest position.
Other hedge funds have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson during the 3rd quarter worth about $31,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC raised its position in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the period. Activest Wealth Management acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $40,000. Finally, Morton Brown Family Wealth LLC boosted its stake in Johnson & Johnson by 400.0% in the 3rd quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company’s stock worth $41,000 after purchasing an additional 200 shares during the period. Institutional investors own 69.55% of the company’s stock.
Insiders Place Their Bets
In other news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Trading Down 2.7 %
Johnson & Johnson stock traded down $3.94 during trading hours on Wednesday, reaching $142.29. The company had a trading volume of 6,330,148 shares, compared to its average volume of 6,856,921. The company has a 50-day moving average price of $150.75 and a 200 day moving average price of $156.23. Johnson & Johnson has a 12-month low of $141.44 and a 12-month high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market cap of $342.58 billion, a price-to-earnings ratio of 20.59, a P/E/G ratio of 2.52 and a beta of 0.51.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period in the prior year, the business posted $2.66 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.49%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- How to Short a Stock in 5 Easy Steps
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Pros And Cons Of Monthly Dividend Stocks
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- The How And Why of Investing in Oil Stocks
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.